Shang Hai Zheng Quan Bao·2026-02-23 19:00Core Viewpoint - The company, Beihai Guofa Chuanshan Biological Co., Ltd., is responding to an inquiry from the Shanghai Stock Exchange regarding its 2025 performance forecast, which includes an expected revenue of approximately 330 million yuan and a net loss of 85 million yuan [2][3]. Financial Data Summary - The company is currently preparing its 2025 annual report, and the disclosed financial data is preliminary and unaudited, subject to adjustments [2]. - The expected revenue for 2025 is approximately 330 million yuan, with a net profit attributable to the parent company projected at -85 million yuan [2][3]. Revenue Breakdown by Business Segment - Pharmaceutical Distribution: Expected revenue growth of 4.43% compared to the previous year, driven by increased sales from centralized procurement and narcotic drugs [4][5]. - Pharmaceutical Manufacturing: Anticipated revenue decline of 23.44%, primarily due to maintenance affecting production capacity and sales policy optimization [6]. - Judicial IVD Business: Expected revenue decrease of 10.00%, attributed to reduced executable orders and intensified market competition [7]. - Other Businesses: Projected revenue growth of 32.74%, mainly due to a low base from the previous year and slight increases in consulting service income [8]. Major Clients and Changes - Pharmaceutical Distribution: The top five clients remain stable, with no significant changes in the client base from 2024 to 2025 [9][10]. - Pharmaceutical Manufacturing: The top five clients are consistent, with minor fluctuations in purchasing amounts due to adjustments in sales policies [11][12]. - Judicial IVD Business: Significant changes in the top five clients due to increased market competition and unsuccessful bids for government contracts [14]. Revenue Recognition Policies - The company maintains consistent revenue recognition policies, with no changes in accounting practices for 2025 [16][17]. - Revenue is recognized when control of the product is transferred to the customer, with specific criteria for direct sales and third-party shipments [28][30]. Market and Industry Analysis - The pharmaceutical distribution market in the North Bay area is expected to grow by approximately 4.0%-4.5% in 2025, influenced by healthcare infrastructure expansion and seasonal public health events [32][33]. - The impact of centralized procurement policies is expected to suppress revenue growth by approximately 1.0-1.5 percentage points due to price reductions [33]. - The company’s revenue growth aligns with industry trends, as comparable companies in the region show varied performance, with growth rates ranging from -1.47% to 5.2% [35].